The most common peptide pairing in the healing space. Two compounds, two mechanisms, one goal: faster recovery from soft-tissue injuries. Mechanistically complementary; human RCTs pending.
Angiogenesis — new blood vessels into damaged tissue. VEGFR2 upregulation. Nitric oxide modulation. Growth factor expression. The 'bring nutrients to the injury' half.
Actin-binding fragment of Thymosin Beta-4. Releases actin monomers so cells can reshape and migrate toward injured tissue. The 'send rebuild crews' half.
BPC-157 provides infrastructure (vasculature); TB-500 moves rebuild cells (fibroblasts, endothelial cells, stem cells) to the work site. Pathways are distinct, so no mechanistic redundancy.
No head-to-head human RCT comparing the stack to either compound alone. User reports are the main evidence for combined efficacy. The mechanism is defensible; the incremental human benefit is still inferred.
Yes — BPC-157 alone is a defensible starting point, especially for acute injuries. TB-500 alone is less common but used for specific cell-migration-relevant issues. Most users who run the stack could get meaningful benefit from BPC-157 alone; they add TB-500 when the injury is complex or recovery stalls.
BPC-157: split morning/evening. TB-500: often done pre-workout or pre-sleep. No strict timing requirement — consistency matters more than precise timing.
Both. Acute injuries tend to respond faster (2-6 weeks). Chronic issues (old injuries, tendinopathy) often need the full 8-12 week cycle. Chronic OA pain is the most variable — results range from dramatic to minimal.
Yes — TB-500's half-life is long enough that 2x/week SC injection maintains therapeutic levels. Some protocols use 2.5mg 2x/week during loading, then drop to 2mg weekly during maintenance.
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
BPC-157 and TB-500 are research-use-only compounds — not FDA-approved for human consumption. The stack protocols described are based on animal research and user reports.
Both are WADA-prohibited substances. Not medical advice. Research use only.